Morgan Stanley Maintains Overweight on CVS Health, Raises Price Target to $106

Benzinga Newsdesk www.benzinga.com Positive 77.1%

Neg 0% Neu 0% Pos 77.1%

Morgan Stanley analyst Erin Wright maintains CVS Health (NYSE:CVS) with a Overweight and raises the price target from $93 to $106.